| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
|
Mayo Clin Proc
|
2015
|
4.70
|
|
2
|
Dose escalation methods in phase I cancer clinical trials.
|
J Natl Cancer Inst
|
2009
|
4.36
|
|
3
|
Tumour heterogeneity in the clinic.
|
Nature
|
2013
|
3.92
|
|
4
|
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.
|
J Clin Oncol
|
2013
|
3.76
|
|
5
|
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
|
J Clin Oncol
|
2004
|
3.67
|
|
6
|
The statins as anticancer agents.
|
Clin Cancer Res
|
2003
|
3.36
|
|
7
|
Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials.
|
J Clin Oncol
|
2005
|
3.34
|
|
8
|
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents.
|
J Clin Oncol
|
2006
|
3.31
|
|
9
|
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
|
J Clin Oncol
|
2007
|
3.16
|
|
10
|
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
|
J Clin Oncol
|
2005
|
2.83
|
|
11
|
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
|
J Clin Oncol
|
2011
|
2.57
|
|
12
|
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
|
J Clin Oncol
|
2005
|
2.52
|
|
13
|
Nasopharyngeal carcinoma: the next challenges.
|
Eur J Cancer
|
2010
|
2.04
|
|
14
|
Randomized phase II trials: inevitable or inadvisable?
|
J Clin Oncol
|
2010
|
2.02
|
|
15
|
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.
|
J Clin Oncol
|
2012
|
1.95
|
|
16
|
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.
|
Clin Cancer Res
|
2010
|
1.93
|
|
17
|
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
|
J Clin Oncol
|
2007
|
1.91
|
|
18
|
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
|
Clin Cancer Res
|
2003
|
1.82
|
|
19
|
Designing transformative clinical trials in the cancer genome era.
|
J Clin Oncol
|
2013
|
1.79
|
|
20
|
Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?
|
J Clin Oncol
|
2003
|
1.71
|
|
21
|
First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting.
|
J Hematol Oncol
|
2008
|
1.70
|
|
22
|
Cancer genomics: technology, discovery, and translation.
|
J Clin Oncol
|
2012
|
1.70
|
|
23
|
Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.
|
J Clin Oncol
|
2005
|
1.69
|
|
24
|
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination.
|
Clin Cancer Res
|
2006
|
1.63
|
|
25
|
Raf kinase as a target for anticancer therapeutics.
|
Mol Cancer Ther
|
2005
|
1.57
|
|
26
|
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
|
J Clin Oncol
|
2007
|
1.53
|
|
27
|
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.
|
Int J Cancer
|
2012
|
1.49
|
|
28
|
Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.49
|
|
29
|
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
|
J Clin Oncol
|
2012
|
1.48
|
|
30
|
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
|
Clin Cancer Res
|
2008
|
1.44
|
|
31
|
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
|
Clin Cancer Res
|
2008
|
1.42
|
|
32
|
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital.
|
BMC Cancer
|
2006
|
1.41
|
|
33
|
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
|
J Clin Oncol
|
2007
|
1.40
|
|
34
|
Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer.
|
Oral Oncol
|
2012
|
1.38
|
|
35
|
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.
|
Clin Cancer Res
|
2010
|
1.35
|
|
36
|
Understanding the attitudes of the elderly towards enrolment into cancer clinical trials.
|
BMC Cancer
|
2006
|
1.33
|
|
37
|
Analysis of treatment practices for elderly cancer patients in Ontario, Canada.
|
J Clin Oncol
|
2005
|
1.31
|
|
38
|
Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.
|
Am J Clin Oncol
|
2006
|
1.29
|
|
39
|
Molecularly targeted oncology therapeutics and prolongation of the QT interval.
|
J Clin Oncol
|
2007
|
1.28
|
|
40
|
Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.
|
J Clin Oncol
|
2013
|
1.28
|
|
41
|
Preclinical development of molecular-targeted agents for cancer.
|
Nat Rev Clin Oncol
|
2010
|
1.27
|
|
42
|
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
|
Clin Cancer Res
|
2007
|
1.26
|
|
43
|
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
Invest New Drugs
|
2014
|
1.23
|
|
44
|
Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
|
J Clin Oncol
|
2010
|
1.23
|
|
45
|
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
|
J Hematol Oncol
|
2014
|
1.20
|
|
46
|
Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
|
Clin Cancer Res
|
2008
|
1.18
|
|
47
|
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.
|
BMC Med
|
2012
|
1.18
|
|
48
|
Ocular toxicity of targeted therapies.
|
J Clin Oncol
|
2012
|
1.17
|
|
49
|
The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
|
Head Neck Oncol
|
2011
|
1.13
|
|
50
|
Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation.
|
Radiother Oncol
|
2012
|
1.12
|
|
51
|
Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents.
|
J Clin Oncol
|
2003
|
1.11
|
|
52
|
Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital.
|
Am J Clin Oncol
|
2008
|
1.11
|
|
53
|
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
|
Clin Cancer Res
|
2011
|
1.07
|
|
54
|
Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
|
Curr Opin Oncol
|
2008
|
1.05
|
|
55
|
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
Invest New Drugs
|
2007
|
1.04
|
|
56
|
Clinical trials in the elderly--a concept comes of age.
|
N Engl J Med
|
2007
|
1.02
|
|
57
|
Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.00
|
|
58
|
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
|
Invest New Drugs
|
2013
|
0.99
|
|
59
|
Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.
|
Cancer Discov
|
2014
|
0.98
|
|
60
|
Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.98
|
|
61
|
Adherence to surveillance guidelines after curative resection for stage II/III colorectal cancer.
|
Clin Colorectal Cancer
|
2008
|
0.98
|
|
62
|
Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer.
|
Cancer
|
2008
|
0.98
|
|
63
|
Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
|
Drug Resist Updat
|
2008
|
0.97
|
|
64
|
Molecular targeted therapy of head and neck cancer: review and clinical development challenges.
|
Eur J Cancer
|
2007
|
0.97
|
|
65
|
Epidermal growth factor receptor targeting in head and neck cancer: have we been just skimming the surface?
|
J Clin Oncol
|
2013
|
0.96
|
|
66
|
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
|
Clin Cancer Res
|
2009
|
0.96
|
|
67
|
Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns.
|
J Clin Oncol
|
2003
|
0.96
|
|
68
|
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
|
Invest New Drugs
|
2015
|
0.96
|
|
69
|
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
|
Invest New Drugs
|
2013
|
0.95
|
|
70
|
The utility of hedgehog signaling pathway inhibition for cancer.
|
Oncologist
|
2012
|
0.94
|
|
71
|
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
|
Mol Cancer Ther
|
2010
|
0.94
|
|
72
|
Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2005
|
0.93
|
|
73
|
Cyclin-dependent kinase inhibitors as potential targeted anticancer agents.
|
Invest New Drugs
|
2009
|
0.93
|
|
74
|
A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix.
|
Eur J Cancer
|
2005
|
0.93
|
|
75
|
The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial.
|
Support Care Cancer
|
2007
|
0.93
|
|
76
|
Rationale for Ras and raf-kinase as a target for cancer therapeutics.
|
Curr Pharm Des
|
2002
|
0.92
|
|
77
|
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
|
Head Neck
|
2009
|
0.92
|
|
78
|
The contents and readability of informed consent forms for oncology clinical trials.
|
Am J Clin Oncol
|
2010
|
0.92
|
|
79
|
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
|
Clin Cancer Res
|
2002
|
0.90
|
|
80
|
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
|
Am J Clin Oncol
|
2012
|
0.90
|
|
81
|
Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.90
|
|
82
|
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
|
BMC Cancer
|
2011
|
0.89
|
|
83
|
Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?
|
BMC Cancer
|
2011
|
0.89
|
|
84
|
Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks.
|
Invest New Drugs
|
2003
|
0.89
|
|
85
|
Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents.
|
J Clin Oncol
|
2008
|
0.88
|
|
86
|
Cardiovascular toxicity of molecularly targeted agents.
|
Eur J Cancer
|
2009
|
0.88
|
|
87
|
Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor.
|
Expert Opin Investig Drugs
|
2008
|
0.88
|
|
88
|
Genomic testing in cancer: patient knowledge, attitudes, and expectations.
|
Cancer
|
2014
|
0.87
|
|
89
|
Improving the quality of abstract reporting for phase I cancer trials.
|
Clin Cancer Res
|
2008
|
0.87
|
|
90
|
Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma.
|
Cancer
|
2002
|
0.86
|
|
91
|
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.
|
Invest New Drugs
|
2005
|
0.85
|
|
92
|
A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.
|
Invest New Drugs
|
2010
|
0.84
|
|
93
|
Targeting the Hedgehog pathway in cancer: can the spines be smoothened?
|
Clin Cancer Res
|
2011
|
0.84
|
|
94
|
A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group.
|
Cancer
|
2010
|
0.83
|
|
95
|
Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial.
|
Support Care Cancer
|
2002
|
0.83
|
|
96
|
Molecular targeted therapies in all histologies of head and neck cancers: an update.
|
Curr Opin Oncol
|
2010
|
0.82
|
|
97
|
Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
|
J Clin Oncol
|
2009
|
0.81
|
|
98
|
Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study.
|
Head Neck
|
2004
|
0.80
|
|
99
|
A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin.
|
Invest New Drugs
|
2014
|
0.80
|
|
100
|
Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors.
|
Anticancer Drugs
|
2006
|
0.80
|
|
101
|
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
|
Invest New Drugs
|
2014
|
0.80
|
|
102
|
Less than ideal: how oncologists practice with limited drug access.
|
J Oncol Pract
|
2012
|
0.79
|
|
103
|
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
|
Am J Clin Oncol
|
2005
|
0.79
|
|
104
|
Principles of clinical trial design.
|
J Clin Oncol
|
2002
|
0.79
|
|
105
|
Clinical genomics information management software linking cancer genome sequence and clinical decisions.
|
Genomics
|
2013
|
0.79
|
|
106
|
Brivanib alaninate for cancer.
|
Expert Opin Investig Drugs
|
2011
|
0.79
|
|
107
|
Phase 1 trial design: is 3 + 3 the best?
|
Cancer Control
|
2014
|
0.79
|
|
108
|
Development of molecular targeted anticancer agents: successes, failures and future directions.
|
Curr Pharm Des
|
2005
|
0.78
|
|
109
|
Clinical trial designs for targeted agents.
|
Hematol Oncol Clin North Am
|
2002
|
0.78
|
|
110
|
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.
|
Cancer
|
2013
|
0.76
|
|
111
|
Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?
|
Expert Rev Pharmacoecon Outcomes Res
|
2014
|
0.76
|
|
112
|
Cancer genomics: the challenge of drug accessibility.
|
Curr Opin Oncol
|
2015
|
0.76
|
|
113
|
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
|
Clin Cancer Res
|
2009
|
0.76
|
|
114
|
Selecting the best drugs for phase I clinical development and beyond.
|
Am Soc Clin Oncol Educ Book
|
2013
|
0.76
|
|
115
|
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
|
Cancer Chemother Pharmacol
|
2005
|
0.75
|
|
116
|
Small tumors, intermediate models, big hopes.
|
J Clin Oncol
|
2010
|
0.75
|
|
117
|
Preface: head and neck cancer.
|
Hematol Oncol Clin North Am
|
2008
|
0.75
|
|
118
|
Clinical trials and biomarker development with molecularly targeted agents and radiotherapy.
|
Cancer Metastasis Rev
|
2008
|
0.75
|
|
119
|
Epstein-Barr virus DNA measured in nasopharyngeal brushings in patients with nasopharyngeal carcinoma: pilot study.
|
J Otolaryngol
|
2004
|
0.75
|
|
120
|
Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT).
|
Invest New Drugs
|
2015
|
0.75
|
|
121
|
Multidisciplinary Symposium on Head and Neck Cancer. 2 December 2005, Philadelphia, PA, USA.
|
Expert Opin Pharmacother
|
2006
|
0.75
|
|
122
|
The influence of mentorship on research productivity in oncology.
|
Am J Clin Oncol
|
2007
|
0.75
|